FIG 1.

Activity of simeprevir against chimeric replicons carrying NS3 sequences derived from pretreatment isolates of hepatitis C virus (HCV) genotype (GT) 1-infected patients by baseline polymorphism (NS3 positions 43, 80, 122, 155, 156, and/or 168). Each data point represents the median simeprevir fold-change (FC) value in 50% effective concentration (EC₅₀) calculated from 1 to 5 repeat transient chimeric replicon experiments of the same clinical isolate (the majority [168 of 224] of clinical isolates depicted in this graph were tested ≥3 times).